These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15223659)

  • 1. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.
    Newsom-Davis T; Bower M; Wildfire A; Thirlwell C; Nelson M; Gazzard B; Stebbing J
    Leuk Lymphoma; 2004 Sep; 45(9):1939-41. PubMed ID: 15223659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
    Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
    Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
    Corbellino M; Bestetti G; Scalamogna C; Calattini S; Galazzi M; Meroni L; Manganaro D; Fasan M; Moroni M; Galli M; Parravicini C
    Blood; 2001 Dec; 98(12):3473-5. PubMed ID: 11719390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
    Pastor MA; Vasco B; Mosquera JM; Debén G; Bautista P; Requena L
    Actas Dermosifiliogr; 2006; 97(6):385-90. PubMed ID: 16956518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
    Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
    AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
    Bower M; Veraitch O; Szydlo R; Charles P; Kelleher P; Gazzard B; Nelson M; Stebbing J
    Blood; 2009 May; 113(19):4521-4. PubMed ID: 19224759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Castleman's disease: from basic mechanisms to molecular therapeutics.
    El-Osta HE; Kurzrock R
    Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders.
    Aoki Y; Tosato G
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):213-25. PubMed ID: 15482187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
    Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
    Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
    Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
    Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
    Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
    Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.
    Awano N; Inomata M; Kondoh K; Satake K; Kamiya H; Moriya A; Ando T; Kumasaka T; Takemura T; Takeuchi K; Ikushima S
    Intern Med; 2012; 51(21):3061-6. PubMed ID: 23124151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.
    Law AB; Ryan G; Lade S; Prince HM
    Int J Hematol; 2010 Mar; 91(2):347-8; author reply 349. PubMed ID: 20146033
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
    Nishi J; Maruyama I
    Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.
    Aoki Y; Tosato G; Fonville TW; Pittaluga S
    Blood; 2001 Apr; 97(8):2526-7. PubMed ID: 11307774
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolonged remission of HIV-associated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy.
    Marrache F; Larroche C; Mémain N; Bouchaud O; Robineau M; Hermine O; Lortholary O
    AIDS; 2003 Jun; 17(9):1409-10. PubMed ID: 12799570
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.
    Reid E; Nooka A; Blackmon J; Lechowicz MJ
    Curr Drug Deliv; 2012 Jan; 9(1):41-51. PubMed ID: 22023215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of multicentric Castleman's disease with bilateral orbital tumour using rituximab.
    Ide M; Ogawa E; Kasagi K; Kawachi Y; Ogino T
    Br J Haematol; 2003 Jun; 121(5):818-9. PubMed ID: 12780800
    [No Abstract]   [Full Text] [Related]  

  • 19. Kaposi's Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology.
    Li S; Bai L; Dong J; Sun R; Lan K
    Adv Exp Med Biol; 2017; 1018():91-127. PubMed ID: 29052134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed by rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease.
    Fragasso A; Mannarella C; Ciancio A; Calvario A; Scarasciulli ML
    Leuk Lymphoma; 2008 Nov; 49(11):2224-6. PubMed ID: 19021070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.